LivaNova PLC Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $1.5B+17.4% YoYTTM through 30 Jun 2026
Net Income $188.6M+198.2% YoYTTM through 30 Jun 2026
Free Cash Flow $148.3MTTM through 30 Jun 2026
Margins
| Current | |
|---|---|
| Gross Margin | 67.7% |
| EBITDA Margin | 17.3% |
| Operating Margin | 14.4% |
| Net Margin | 12.8% |
Returns
-20.2%ROE
-9.3%ROA
17.2%ROIC
Balance Sheet Health
Debt / Equity0.31x
Current Ratio1.36x
Net Debt-$258.9Mnet cash position
Cash & Equivalents$516.6M
Quality Metrics
Altman Z-Score2.36
Piotroski F-Score8 / 9
FCF Margin10.1%
Rule of 4013.3
Earnings-Beat Rate100.0%
Multi-Year Trend
RevenueFY2025: $1.4B
Diluted EPS-$4.45TTMFY2025: $-4.45
Dividend
No dividend
Capital Allocation
R&D Spend$213.1M
Capex Intensity6.9%
Segment Performance
| Segment | Revenue | YoY | Outlook |
|---|---|---|---|
| Cardiopulmonary | $818.1M | +14.9% | View detailsExpected to maintain solid growth momentum in 2026 with continued global rollout of the Essenz Perfusion System. |
| Neuromodulation | $554.2M | +7.0% | View detailsAnticipating further expansion in 2026 supported by increased Medicare reimbursement rates for VNS Therapy. |
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.